European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"[⁶⁸Ga]Ga-Trivehexin PET/CT imaging of integrin-αvβ6 expression in concomitant mucinous lung adenocarcinoma and idiopathic pulmonary fibrosis.","authors":"Huiqin Wu, Ling Li, Zhiwei Xiao, Qiongrong Chen, Chongjiao Li, Yong He","doi":"10.1007/s00259-025-07146-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07146-w","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subendocardial quantification enhances coronary artery disease detection in 18F-flurpiridaz PET","authors":"Valerie Builoff, Mark Lemley, Robert J. H. Miller, Hidesato Fujito, Giselle Ramirez, Paul Kavanagh, Christopher Buckley, Marcelo Di Carli, Daniel S. Berman, Piotr Slomka","doi":"10.1007/s00259-025-07174-6","DOIUrl":"https://doi.org/10.1007/s00259-025-07174-6","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>The new high resolution positron emission tomography (PET) myocardial perfusion imaging tracer, ¹⁸F-flurpiridaz, is set to enter clinical use soon following its recent regulatory approval. We developed an approach for evaluating subendocardial analysis for stress total perfusion deficit (TPD) and ischemic TPD, assessed its performance for detection of coronary artery disease (CAD) and compared these measures to transmural analysis and expert physician assessments.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Myocardial perfusion image data from the ¹⁸F-flurpiridaz phase III clinical trial (NCT01347710) were used. The subendocardial layer was automatically defined on the left ventricular contours and used for the derivation of polar maps. Areas under the receiver operating characteristic curve (AUC) for quantitative and visual measures were evaluated for detecting CAD, defined as ≥ 50% stenosis by invasive coronary angiography.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>In total, 753 cases were analyzed, with a median age of 63 (interquartile range 56,69) and 69% male. AUC for detecting ≥ 50% stenosis was higher for subendocardial than transmural analysis for stress (0.795 vs. 0.762, respectively; <i>p</i> = 0.013) and ischemic (0.795 vs. 0.767, respectively; <i>p</i> = 0.049) TPD. Subendocardial and transmural TPD achieved diagnostic performance greater than or comparable to that of the readers’ assessments in the total population as well as across subgroups of interest.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Subendocardial analysis of ischemic perfusion improves the detection of CAD compared to transmural quantitative analysis or expert visual reading. These measures can be derived automatically with minimal user interaction. Integrating TPD quantitative measures could standardize the diagnostic approach for this novel tracer.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"3 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143546211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing non-invasive quantitative methods for [18F]SynVesT-1 PET imaging of synaptic vesicle glycoprotein 2A in the rat brain","authors":"Lori Berckmans, Claudia Schrauwen, Alan Miranda, Steven Staelens, Daniele Bertoglio","doi":"10.1007/s00259-025-07170-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07170-w","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Synaptic vesicle glycoprotein 2A (SV2A) is a critical biomarker for evaluating synaptic density in neurological research. Among available radioligands, [¹⁸F]SynVesT-1 is increasingly used in PET research because of its extended half-life, while having comparable pharmacokinetic properties to the widely used [¹¹C]UCB-J. However, quantitative application in rat models remains unexplored for [¹⁸F]SynVesT-1. This study aims to validate quantitative kinetic modelling methods for [¹⁸F]SynVesT-1 and develop non-invasive quantification methods for synaptic density in rats.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>First, blood analysis of [¹⁸F]SynVesT-1 was performed to generate metabolite-corrected plasma input functions. Then, kinetic modelling was evaluated using compartmental analysis approaches, as well as Logan plot. Furthermore, non-invasive image-derived input functions (IDIF), with and without non-negative matrix factorization (NMF) were compared against the arterial input function (AIF).</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Blood analysis showed that the parent fraction of the tracer decreased over time following a sigmoid curve, while the plasma-to-whole blood ratio remained stable over time (0.89 ± 0.02). The two-tissue compartmental model (2TCM) and Logan plot were determined to be the most accurate methods for quantification of [¹⁸F]SynVesT-1 kinetics in rats. Additionally, the results demonstrated strong agreement between AIF-derived and image-derived volume of distribution (<i>V</i>_T) values, with both image-derived input approaches (IDIF and IDIF-NMF) performing equally well.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>These findings validate kinetic modelling methods for [¹⁸F]SynVesT-1 PET, enabling their application in further rat studies for preclinical neuroscience research and prove that image-derived input functions are reliable non-invasive alternatives to AIF.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"9 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical and first‑in‑human evaluation of [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P PET imaging to assess tumor PD-L1 expression","authors":"Yang Chen, Yinting Hu, Ao Li, Guojin Zhang, Danyi Guo, Xinchao Yao, Baozhen Zeng, Ganghua Tang, Benyuan Jiang, Lei Jiang","doi":"10.1007/s00259-025-07173-7","DOIUrl":"https://doi.org/10.1007/s00259-025-07173-7","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>PD-L1 PET imaging can provide a non-invasively and real-time assessment of PD-L1 expression status at tumor sites. This study aimed to evaluate the targeting efficacy and biodistribution of a novel peptide-based PD-L1 PET agent, [⁶⁸Ga]Ga-DOTA-PEG₂-Asp₂-PDL1P, in preclinical studies and human participants.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>[⁶⁸Ga]Ga-DOTA-PEG₂-Asp₂-PDL1P was synthesized and the probe stability was analyzed in vitro and in vivo. Cellular uptake of the probe was evaluated using tumor cell lines with different PD-L1 expression levels. Small animal PET imaging and semi-quantitative studies were conducted in PC3, H1975 and A549 tumor-bearing mice models, with tumor PD-L1 expression confirmed through immunofluorescence and immunohistochemistry. Furthermore, [⁶⁸Ga]Ga-DOTA-PEG₂-Asp₂-PDL1P PET imaging was performed in 1 healthy volunteer and 14 lung cancer patients to assess biodistribution and PD-L1 expression at tumor sites.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>[⁶⁸Ga]Ga-DOTA-PEG₂-Asp₂-PDL1P exhibited a radiochemical purity of &gt; 99% and had good stability both in vitro and in vivo. In vitro cellular uptake and in vivo small animal PET imaging revealed the probe binding to PD-L1 with high affinity and specificity, consistent with the results of immunofluorescence and immunohistochemistry. In the clinical study involving 15 participants, [⁶⁸Ga]Ga-DOTA-PEG₂-Asp₂-PDL1P was proven safe with demonstrating low uptake in normal organs and physiologically excreting via the urinary system. Lung cancer patients with high PD-L1 expression (TPS 70-90%) exhibited higher tumor uptake and tumor-to-background ratios than those with negative or low PD-L1 expression (TPS &lt; 1-10%), with SUVmax of 1.89–2.27 vs. 0.87–1.01, tumor-to-lung ratios of 4.73–7.68 vs. 1.61–2.35, and tumor-to-muscle ratios of 6.73–12.61 vs. 4.35–5.61.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>[⁶⁸Ga]Ga-DOTA-PEG₂-Asp₂-PDL1P showed promising as a PET agent to assess tumor PD-L1 expression in preclinical and first-in-human studies, offering a non-invasive, real-time and accurate tool to address clinical challenges in predicting and assessing the efficacy of immunotherapy.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"34 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143532807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase I study of [⁶⁸Ga]Ga-HX01 for targeting integrin αvβ3 and CD13 in healthy and malignancy subjects.","authors":"Xiao Zhang, Hanyi Fang, Biao Yang, Chunxia Qin, Fan Hu, Weiwei Ruan, Jing Chen, Dexing Zeng, Yongkang Gai, Xiaoli Lan","doi":"10.1007/s00259-024-07002-3","DOIUrl":"10.1007/s00259-024-07002-3","url":null,"abstract":"<p><strong>Purpose: </strong>Noninvasive angiogenesis visualization is essential for evaluating tumor proliferation, progression, invasion, and metastasis. This study aimed to translate the heterodimeric PET tracer [⁶⁸Ga]Ga-HX01, which targets integrin αvβ3 and CD13 in neovascularization, into phase I clinical study.</p><p><strong>Methods: </strong>This study enrolled 12 healthy volunteers (phase Ia) and 10 patients with malignant tumors (phase Ib). The subjects in phase Ia were divided into low-dose (0.05 mCi/kg) and high-dose (0.1 mCi/kg) groups. For phase Ia subjects, PET/CT images, blood and urine samples were collected to analyze the biodistribution, pharmacokinetics, radiation dosimetry, and safety of [⁶⁸Ga]Ga-HX01. For phase Ib patients, PET/MR scans were performed at 30 ± 5 and 60 ± 5 min after injection. The safety and preliminary diagnostic value of [⁶⁸Ga]Ga-HX01 were assessed.</p><p><strong>Results: </strong>In phase Ia study, [⁶⁸Ga]Ga-HX01 was distributed and metabolized similarly in two dosage groups as the highest accumulations in kidneys and urine. It possessed quick renal excretion and blood clearance with an elimination half-life (T_1/2) of 28.92 ± 3.97 min. The total effective dose was 2.14 × 10^- 2 mSv/MBq. In phase Ib study, [⁶⁸Ga]Ga-HX01 clearly detected the lesions per patient, and found a total of 59 lesions with varying uptake levels. For safety evaluation, no serious adverse events were observed during the examination.</p><p><strong>Conclusion: </strong>[⁶⁸Ga]Ga-HX01 has proved to be a translational radiopharmaceutical with reliable security, favorable pharmacokinetics, and the ability to visualize tumors. The preliminary results in malignancy patients warrant further investigation of [⁶⁸Ga]Ga-HX01 in monitoring antiangiogenic therapy of patients with malignancies.</p><p><strong>Clinical trial registration: </strong>ClinicalTrials.gov, NCT06416774. Registered 11 May, 2024.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"1293-1304"},"PeriodicalIF":8.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"α_vβ₆-integrin targeted [⁶⁸Ga]Ga-Trivehexin PET/CT imaging of a rare bronchial mucoepidermoid carcinoma.","authors":"Huiqin Wu, Ling Li, Zhiwei Xiao, Chongjiao Li, Yong He","doi":"10.1007/s00259-024-06974-6","DOIUrl":"10.1007/s00259-024-06974-6","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"1291-1292"},"PeriodicalIF":8.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of early-phase β-amyloid positron-emission-tomography and neuropsychological testing in patients with Alzheimer’s disease","authors":"Friederike Völter, Sebastian Eckenweber, Maximilian Scheifele, Florian Eckenweber, Fabian Hirsch, Nicolai Franzmeier, Annika Kreuzer, Maria Griessl, Anna Steward, Daniel Janowitz, Carla Palleis, Alexander Bernhardt, Jonathan Vöglein, Anna Stockbauer, Boris-Stephan Rauchmann, Florian Schöberl, Elisabeth Wlasich, Katharina Buerger, Olivia Wagemann, Robert Perneczky, Endy Weidinger, Günter Höglinger, Johannes Levin, Matthias Brendel, Sonja Schönecker","doi":"10.1007/s00259-025-07175-5","DOIUrl":"https://doi.org/10.1007/s00259-025-07175-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Clinical staging in individuals with Alzheimer’s disease (AD) typically relies on neuropsychological testing. Recognizing the imperative for an objective measure of clinical AD staging, regional perfusion in early-phase β-amyloid-PET may aid as a cost-efficient index for the assessment of neurodegeneration severity in patients with Alzheimer’s disease.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Regional perfusion deficits in early-phase β-amyloid-PET as well as neuropsychological testing (max. 90 days delay) were evaluated in 82 patients with biologically defined AD according to the ATN classification. In reference to the Braak staging system patients were classified into the groups stage⁰, stage^I−II+, stage^I−IV+, stage^I−VI+, and stage^atypical+ according to regional perfusion deficits in regions of interest (ROIs) published by the Alzheimer’s Disease Neuroimaging Initiative. Multiple regression analysis controlling for age, gender, and education was used to evaluate the association of regional z-scores on perfusion-phase PET with clinical scores for all patients and with annual decline of cognitive performance in 23 patients with follow-up data.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Patients classified as stage⁰ and stage^I−II+ demonstrated significantly superior neuropsychological performance compared to those classified as stage^I−IV+ and stage^I−VI+. Lower cognitive performance was associated with decreased perfusion in early-phase β-amyloid-PET globally and regionally, with the most pronounced association identified in the left temporal lobe. Mean z-scores on early-phase PET in temporal and parietal regions offered a robust prediction of future annual decline in MMSE and sum scores of the CERAD-Plus (Consortium to Establish a Registry for Alzheimer’s Disease) test battery.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Regional and global perfusion deficits in early-phase β-amyloid-PET can serve as an objective index of neurodegeneration severity and may act as prognostic markers of future cognitive decline in AD.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"32 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of [68Ga]Ga-FAPI-04 PET in patients with newly diagnosed gastric carcinoma","authors":"Chunxia Qin, Yiru Fu, Xiao Zhang, Mengting Li, Weiwei Ruan, Yongkang Gai, Xiaoli Lan","doi":"10.1007/s00259-025-07164-8","DOIUrl":"https://doi.org/10.1007/s00259-025-07164-8","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Gallium-68-labeled fibroblast activation protein inhibitor ([⁶⁸Ga]Ga-FAPI) positron emission tomography (PET) has demonstrated excellent diagnostic performance in various malignancies, including gastric carcinoma. However, its prognostic utility is unclear. This study evaluates the prognostic value of [⁶⁸Ga]Ga-FAPI-04 PET/MRI(CT) in gastric carcinoma.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We retrospectively analyzed patients with gastric cancer who underwent [⁶⁸Ga]Ga-FAPI-04 PET/MRI(CT) between June 2020 and June 2023. Semi-quantitative parameters, including maximum and mean standard uptake value (SUVmax, SUVmean), FAPI-avid tumor volume (FTV), total lesion FAP expression (TLF), tumor to background ratio (TBR), heterogeneity factor (HF) and coefficient of variation (CV) of the primary tumor were measured or calculated. Overall survival (OS) and progression-free survival (PFS) were obtained through follow-up. The relationships between disease prognosis and potential predictors were analyzed， and predictive models were established.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Eighty-six patients (median age 59 years) were included. Thirty-five patients experienced disease progression, and 26 of them died. Univariable analysis revealed SUVmax, FTV, TLF, TBR, HF and CV were significant prognostic factors for both OS and PFS. In multivariate Cox regression analysis, a nomogram model for OS was established, incorporating body mass index (BMI) and CV as independent predictors. The time-dependent C-index of the nomogram model &gt; 0.75 indicates good predictive performance. When predicting PFS, a stratified analysis was performed based on distant metastasis, FTV was an independent prognostic factor among patients without distant metastasis.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>CV and FTV, derived from [⁶⁸Ga]Ga-FAPI-04 PET imaging, could serve as independent prognostic factor for OS and PFS in patients with gastric cancer, respectively.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"27 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhanced diagnostic and prognostic assessment of cardiac amyloidosis using combined 11C-PiB PET/CT and 99mTc-DPD scintigraphy","authors":"Zhihui Hong, Clemens P. Spielvogel, Song Xue, Raffaella Calabretta, Zewen Jiang, Josef Yu, Kilian Kluge, David Haberl, Christian Nitsche, Stefan Grünert, Marcus Hacker, Xiang Li","doi":"10.1007/s00259-025-07157-7","DOIUrl":"https://doi.org/10.1007/s00259-025-07157-7","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Cardiac amyloidosis (CA) is a severe condition characterized by amyloid fibril deposition in the myocardium, leading to restrictive cardiomyopathy and heart failure. Differentiating between amyloidosis subtypes is crucial due to distinct treatment strategies. The individual conventional diagnostic methods lack the accuracy needed for effective subtype identification. This study aimed to evaluate the efficacy of combining ¹¹C-PiB PET/CT and ^99mTc-DPD scintigraphy in detecting CA and distinguishing between its main subtypes, light chain (AL) and transthyretin (ATTR) amyloidosis while assessing the association of imaging findings with patient prognosis.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We retrospectively evaluated the diagnostic efficacy of combining ¹¹C-PiB PET/CT and ^99mTc-DPD scintigraphy in a cohort of 50 patients with clinical suspicion of CA. Semi-quantitative imaging markers were extracted from the images. Diagnostic performance was calculated against biopsy results or genetic testing. Both machine learning models and a rationale-based model were developed to detect CA and classify subtypes. Survival prediction over five years was assessed using a random survival forest model. Prognostic value was assessed using Kaplan-Meier estimators and Cox proportional hazards models.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The combined imaging approach significantly improved diagnostic accuracy, with ¹¹C-PiB PET and ^99mTc-DPD scintigraphy showing complementary strengths in detecting AL and ATTR, respectively. The machine learning model achieved an AUC of 0.94 (95% CI 0.93–0.95) for CA subtype differentiation, while the rationale-based model demonstrated strong diagnostic ability with AUCs of 0.95 (95% CI 0.88-1.00) for ATTR and 0.88 (95% CI 0.770–0.961) for AL. Survival prediction models identified key prognostic markers, with significant stratification of overall mortality based on predicted survival (<i>p</i> value = 0.006; adj HR 2.43 [95% CI 1.03–5.71]).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The integration of ¹¹C-PiB PET/CT and ^99mTc-DPD scintigraphy, supported by both machine learning and rationale-based models, enhances the diagnostic accuracy and prognostic assessment of cardiac amyloidosis, with significant implications for clinical practice.</p><h3 data-test=\"abstract-sub-heading\">Graphical abstracts</h3>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"51 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the landscape of current in vitro and in vivo models and their relevance for targeted radionuclide theranostics","authors":"Lisa Bokhout, Joana D. Campeiro, Simone U. Dalm","doi":"10.1007/s00259-025-07123-3","DOIUrl":"https://doi.org/10.1007/s00259-025-07123-3","url":null,"abstract":"<p>Cancer remains a leading cause of mortality globally, driving ongoing research into innovative treatment strategies. Preclinical research forms the base for developing these novel treatments, using both in vitro and in vivo model systems that are, ideally, as clinically representative as possible. Emerging as a promising approach for cancer management, targeted radionuclide theranostics (TRT) uses radiotracers to deliver (cytotoxic) radionuclides specifically to cancer cells. Since the field is relatively new, more advanced preclinical models are not yet regularly applied in TRT research. This narrative review examines the currently applied in vitro, ex vivo and in vivo models for oncological research, discusses if and how these models are now applied for TRT studies, and whether not yet applied models can be of benefit for the field. A selection of different models is discussed, ranging from in vitro two-dimensional (2D) and three-dimensional (3D) cell models, including spheroids, organoids and tissue slice cultures, to in vivo mouse cancer models, such as cellline-derived models, patient-derived xenograft models and humanized models. Each of the models has advantages and limitations for studying human cancer biology, radiopharmaceutical assessment and treatment efficacy. Overall, there is a need to apply more advanced models in TRT research that better address specific TRT phenomena, such as crossfire and abscopal effects, to enhance the clinical relevance and effectiveness of preclinical TRT evaluations.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"11 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}